

Media Release

Proteome Systems Limited ACN 080 277 998



Media contact:

Susan Fitzpatrick

DatelineMedia

Susan.fitzpatrick@DatelineMedia.com

Australia Office: +1 61 2 90061614

USA Office +1 650 279 7771

FOR IMMEDIATE RELEASE

29 August 2006

Proteome Systems collaborates with Westmead Hospital on Prostate Cancer Diagnostic Test

Sydney, Australia: Proteome Systems (ASX:PXL) today announced a collaboration with Dr Andrew Brooks, Clinical Urologist at Westmead Hospital and Head of the Urological Cancer Organisation, to combine their expertise in prostate cancer for the rapid development of an advanced diagnostic product.

- *Prostate cancer represents a significant clinical challenge and opportunity. Around 1 man in 6 in the US will be diagnosed with prostate cancer during his lifetime, with 1 man in 34 dying from the disease, according to the American Cancer Society.*
- *If prostate cancer is detected early there is a greater chance for active management and improved health and lifestyle outcomes for men. Although the current PSA test is useful there is a need for a more accurate diagnostic test.*
- *US based Egenix has patented a novel carbohydrate candidate marker for prostate cancer, Human Carcinoma Antigen (HCA), and has licensed this Intellectual Property to PXL for the joint development of a new prostate cancer diagnostic test. Proteome Systems has used its acknowledged proteomic and glycoproteomic expertise to further develop the HCA marker towards a test with higher specificity than the current PSA test.*

Sydney based Westmead Hospital is recognised as a leading institute for the diagnosis and treatment of prostate cancer. The collaboration will involve obtaining semen and blood samples from patients who have had biopsies as a result of an increased PSA level. Some of these biopsies will indicate prostate cancer whereas others will be found to be disease free. These samples will be used by Proteome Systems to continue to develop its diagnostic test using the HCA biomarker to better differentiate the presence of prostate cancer in men with elevated PSA.

Dr. Andrew Brooks leads a team to improve the management of urological cancers by co-ordinating clinical care and research activities throughout western Sydney and the greater west of NSW. He is a leader in the diagnosis and treatment of prostate related disease in Australia.

Mr. Stephen Porges, CEO of Proteome Systems said he "is delighted to be collaborating with an outstanding team of clinicians to complement our glycoproteomic expertise. Our recent success in this programme led by Dr. Nicolle Packer shows the ability of our team to characterise novel biomarkers. The clinical expertise and high quality samples provided by Dr Brooks and his team are critical to a successful outcome of the development of a test to diagnose and monitor prostate cancer."

Background on Proteome Systems:

1/35 Waterloo Road, North Ryde Sydney NSW 2113 Australia
Locked Bag 2073, North Ryde Sydney NSW 1670 Australia
Phone: +61 2 9889 1830 Fax: +61 2 9889 1805 www.proteomesystems.com
Proteome Systems Limited ACN 080 277 998

Proteome Systems Limited [ASX:PXL] is a dynamic biotechnology company which discovers and develops diagnostics and therapeutic products. The Company has extensive expertise in the discovery and development of protein and glycoprotein biomarkers, with a focus on diseases for which there are large global markets and unmet need for diagnostics and drugs such as, respiratory disease, neurobiology, neurodegenerative disease, cancer and infectious diseases. PXL's scientific leadership is demonstrated by its track record in partnering with leading US and European companies, clinical groups and research institutions to collaborate on its research programmes and to develop the outcomes of its research for diagnostic and therapeutic application. In March 2006, PXL entered an agreement with Egenix Inc, to develop a semen-based test for prostate cancer. Additional information about Proteome Systems can be found at www.proteomesystems.com.

Background on Urological Cancer Organisation

The Urological Cancer Organisation (UCO) is a multi-disciplinary organisation established in 2001 whose aim is to improve treatment outcomes for patients with urological cancer by collaboration and cooperation between all stakeholders in the patient's cancer journey. UCO has a geographic based constituency in Western Sydney and is centred at Westmead Hospital. The organisation has a proven track record in the conduct of multi disciplinary team management of cancer, cancer treatment protocol development and recruitment for and conduct of clinical trials.

For further information contact:

Jenny Harry
Deputy CEO,
Head of Diagnostics & Discovery
Proteome Systems Limited
Phone: 02 8877 8947